ReviewJournal of clinical medicine2021
Acute and Preventive Management of Migraine during Menstruation and Menopause.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Multidisciplinary Management of Women Suffering from Migraine: Rationale, Design and Results of a National Delphi Consensus.Healthcare (Basel, Switzerland) · 2026Article
- Evolving care pathways for women with migraine in Italy: results from a national survey.Frontiers in neurology · 2026Article
- Short-term prevention of perimenstrual migraine with rimegepant.The journal of headache and pain · 2025Article
- Underdiagnosis and impact of menstrual migraine in real-world clinical practice: A real-world survey.Headache · 2025Article
- Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment.Neurology and therapy · 2025Review
- Prevalence, Treatment, and Unmet Needs of Migraine in the Middle East: A Systematic Review.Pain and therapy · 2025Review
- The Efficacy and Safety of Electroacupuncture for Prophylaxis of Menstrually Related Migraine: Study Protocol for a Pilot Randomized Controlled Trial.International journal of women's health · 2025Article
- Understanding the Biological Relationship between Migraine and Depression.Biomolecules · 2024Review
- Study to Determine the Prevalence of Menstrual Migraine in Reproductive-Age Women in Saudi Arabia.Healthcare (Basel, Switzerland) · 2024Article
- Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel.Frontiers in neurology · 2024Article
- Considerations for hormonal therapy in migraine patients: a critical review of current practice.Expert review of neurotherapeutics · 2023Review
- Comorbidities of Rural Children and Adolescents with Migraine and without Migraine.Children (Basel, Switzerland) · 2023Article
- Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients.Pain and therapy · 2021Article
- Genetics of Menstrual Migraine and Their Association with Female Hormonal Factors.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine course is influenced by female reproductive milestones, including menstruation and perimenopause; menstrual migraine (MM) represents a distinct clinical entity. Increased susceptibility to migraine during menstruation and in perimenopause is probably due to fluctuations in estrogen levels. The present review provides suggestions for the treatment of MM and perimenopausal migraine. MM is characterized by long, severe, and poorly treatable headaches, for which the use of long-acting triptans and/or combined treatment with triptans and common analgesics is advisable. Short-term prophylaxis with triptans and/or estrogen treatment is another viable option in women with regular menstrual cycles or treated with combined hormonal contraceptives; conventional prevention may also be considered depending on the attack-related disability and the presence of attacks unrelated to menstruation. In women with perimenopausal migraine, hormonal treatments should aim at avoiding estrogen fluctuations. Future research on migraine treatments will benefit from the ascertainment of the interplay between female sex hormones and the mechanisms of migraine pathogenesis, including the calcitonin gene-related peptide pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.